MiNK Therapeutics
INKT
25 hedge funds and large institutions have $1.76M invested in MiNK Therapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
19% more funds holding
Funds holding: 21 → 25 (+4)
0.17% less ownership
Funds ownership: 0.4% → 0.23% (-0.17%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
70% less capital invested
Capital invested by funds: $5.96M → $1.76M (-$4.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$107K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$31K |
| 3 |
BlackRock
New York
|
+$21.7K |
| 4 |
State Street
Boston,
Massachusetts
|
+$14.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$1.86M |
| 2 |
Millennium Management
New York
|
-$306K |
| 3 |
GTCM
Gyon Technologies Capital Management
Denville,
New Jersey
|
-$189K |
| 4 |
Morgan Stanley
New York
|
-$128K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$94K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.11K | -37 | -76% |
|
27
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$30 | +1 | New |
|
28
Fidelity Investments
Boston,
Massachusetts
| – | +$481 | +16 | New |
|
INKT Hedge Fund Activity: Q1 2022 in Review
25 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q1 2022, worth a combined $1.76M — down 70% from $5.96M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new INKT positions and 4 closed out — a net gain of 4 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $107K. The largest seller was RTW Investments, exiting entirely with an estimated $1.86M sold.
- 25 institutional investors held MiNK Therapeutics (INKT) as of Q1 2022, up from 21 in Q4 2021.
- Funds reported $1.76M of MiNK Therapeutics stock for Q1 2022, down 70% quarter-over-quarter.
- 8 funds opened new MiNK Therapeutics positions in Q1 2022 and 4 closed out, a net change of +4 holders.
- The largest MiNK Therapeutics buyer in Q1 2022 was Bridgeway Capital Management, an estimated $107K added.
- The largest MiNK Therapeutics seller in Q1 2022 was RTW Investments, an estimated $1.86M sold.
Based on aggregated 13F filings for Q1 2022.